Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences

Abstract

BackgroundGenetic testing for hereditary cancer syndromes has been revolutionized by next-generation sequencing, which allows for simultaneous review of numerous genes. Multigene panels are regularly offered to patients because of their scope and decreased cost and turnaround time. However, many genes included on larger panels have not been studied as extensively as BRCA1 and BRCA2 (BRCA1/2), and their clinical effects are often not as well established.MethodsWe identified patients who received positive test results for pathogenic variants of breast cancer genes from January 2012 through May 2018. We mailed a survey and conducted qualitative interviews to explore the personal and health care experiences of patients with pathogenic variants of BRCA1/2 and patients with “other” (ie, non-BRCA1/2 or PALB2; PTEN; ATM; TP53; NBM, RAD51C; MSH6) variants. We compared the experiences of these patients.ResultsFifty-nine out of 128 individuals responded to the survey (46%). Thirty-two patients had BRCA1/2 variants, and 27 had other variants. (49 women and 10 men; median [range] age, 63 [34–87] years). We interviewed 21 patients (17 women and 4 men; median [range] age, 59.6 [34–82] years). Of the interview participants, ten patients had BRCA1/2 variants, and 11 had non-BRCA1/2 variants. Patients reported receiving poor information about their genetic test results, and they often educated their physicians about their results. Some patients believed that they had been ignored or “brushed off” by health care professionals because non-BRCA1/2 genes are less understood outside the genetics research community. Patients with BRCA1/2 variants had similar problems with health care providers, despite increased awareness and established guidelines about BRCA1/2.ConclusionsResearch is required to understand the clinical significance and proper management of diseases attributable to newly characterized hereditary cancer genes. Additional evaluation of patient and provider education should be at the forefront of efforts to improve patient care.

Development of a person-centred digital platform for the long-term support of people living with an adult-onset genetic disease predisposition: a mixed-methods study protocol

“… 21 Nevertheless, patients are often ill informed and not following the most up-to-date management guidelines. 22 Consumer advocacy and support groups in the high-risk breast cancer setting 23 endeavour to fill this void but women still call for ‘unambiguous, clear and unified information from health professionals’ to counteract conflicting advice 24 and limited knowledge 25 from non-genetic specialists.…”

Leading Canadian Nurses into the Genomic Era of Healthcare

“…Recognizing and understanding the ethical issues associated with genomics and genetic testing will support ethical practice. As many genetic conditions are inherited in families, personal decisions to have predictive genetic testing impact others for generations to come (Clift et al 2019;Meiser et al 2016;Pollard et al 2020). Decisions around genetic testing can be influenced by concerns for discrimination, historical traumas and racial bias (Allen 2018;Bentley et al 2017;de Mendoza et al 2018).…”